^
Association details:
| Biomarker: | EZH2 mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | SHR-2554 (EZH2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma
Published date:
08/24/2021
Excerpt:
The novel EZH2 inhibitor SHR2554 inhibited proliferation and induced G1 phase arrest in EZH2-mutant DLBCL cell lines. The combination of EZH2 inhibitor SHR2554 with histone deacetylase (HDAC) inhibitor chidamide (hereafter referred to as HBI8000) exerted synergistic anti-proliferative activity in vitro and in vivo.
DOI:
10.3390/cancers13174249
